In addition, combining multiomics studies to explore the specific signaling pathways and key factors involved in the APOB/APOA1 affecting valve calcification will help to investigate therapeutic agents targeting these pathways and key factors, thereby slowing down the progression of CAVD. Here, APOA1 is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.